NCT05813561View on ClinicalTrials.gov

The Efficacy and Safety of DWP14012 in Chinese Patients With Reflux Esophagitis

PHASE3CompletedINTERVENTIONAL
Enrollment

332

Participants

Timeline

Start Date

December 30, 2021

Primary Completion Date

July 23, 2022

Study Completion Date

February 17, 2023

Conditions
Reflux Esophagitis
Interventions
DRUG

DWP14012

DWP14012 40mg

Trial Locations (1)

Unknown

Minhu Chen, Guangzhou

Sponsors
All Listed Sponsors
lead

Daewoong Pharmaceutical Co. LTD.

INDUSTRY

NCT05813561 - The Efficacy and Safety of DWP14012 in Chinese Patients With Reflux Esophagitis | Biotech Hunter | Biotech Hunter